Preview Mode Links will not work in preview mode

Emergency Medical Minute


Nov 15, 2021

Contributor: Jared Scott, MD

Educational Pearls:

  • A press release from Merck introduced Molnupiravir for treatment of mild to moderate COVID-19
  • The yet to be published study is a randomized control trial at around 100 different sites
  • Reported outcomes were hospitalization and mortality from COVID and mortality from COVID
  • Molnupiravir was found to be twice as effective as placebo looking at these two endpoints (7% vs. 14%)
  • 5 day course of the drug taken twice per day costs $700, but cost-saved from using this drug was $32,000 per patient


Summarized by John Spartz, MS4 | Edited by Erik Verzemnieks, MD

The Emergency Medical Minute is excited to announce that we are now offering AMA PRA Category 1 credits™ via online course modules. To access these and for more information, visit our website at and create an account. 

Donate to EMM today!

Diversity and Inclusion Award